Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi, China.
J Pediatr Endocrinol Metab. 2021 Jun 28;34(9):1139-1146. doi: 10.1515/jpem-2020-0733. Print 2021 Sep 27.
An increase in the incidence of congenital hypothyroidism (CH) with eutopic gland has been reported worldwide due to neonatal screening programs. In this study, we aimed to determine the prevalence of transient CH (TCH) and to investigate predictive factors that could distinguish between permanent and transient CH in patients with eutopic thyroid glands.
We retrospectively reviewed 508 children treated for CH with eutopic thyroid glands between June 1998 and June 2020 in Jiangxi Newborn Screening Center. All patients were treated with levothyroxine and underwent Diagnostic re-evaluation after 2-3 years of age. Patients were classified as having TCH or permanent CH (PCH) during follow-up.
Of the 508 patients initially treated for CH with a normally located gland, 335 patients (65.9%) were classified in the TCH group and 173 (34.1%) in the PCH group based on the defined criteria. Multivariate analysis revealed that TCH was associated with a lower levothyroxine dose at 24 months of age (p<0.001) and a lower likelihood of having a first-degree family history of CH (p=0.026) than PCH. Gender, prematurity, low birth weight, initial CH severity such as serum TSH and FT4 levels, or bone maturation delay at diagnosis had no effect. Receiver operating characteristics curve analysis showed that a cutoff of 2.3 μg/kg/day for levothyroxine dose requirement at 24 months of age had a sensitivity of 71% and a specificity of 70% for predicting transient CH, with values below this threshold considered predictive of transient CH.
TCH presents a significant portion of patients with CH. The levothyroxine dose requirement at 24 months of age has a predictive role in differentiating TCH from PCH in CH patients with eutopic thyroid glands.
由于新生儿筛查计划,全世界范围内报道了伴有正常位置腺体的先天性甲状腺功能减退症(CH)发病率增加。本研究旨在确定暂时性 CH(TCH)的患病率,并探讨能够区分伴正常位置腺体 CH 患者中永久性和暂时性 CH 的预测因素。
我们回顾性分析了 1998 年 6 月至 2020 年 6 月在江西新生儿筛查中心接受治疗的 508 例伴正常位置腺体 CH 患儿。所有患者均接受左甲状腺素治疗,并在 2-3 岁后进行诊断性再评估。在随访期间,患者被分为 TCH 或永久性 CH(PCH)。
在最初接受伴正常位置腺体 CH 治疗的 508 例患者中,根据定义的标准,335 例(65.9%)患者被归类为 TCH 组,173 例(34.1%)患者被归类为 PCH 组。多变量分析显示,与 PCH 相比,TCH 与 24 个月时较低的左甲状腺素剂量(p<0.001)和较低的一级 CH 家族史可能性(p=0.026)相关。性别、早产、低出生体重、初始 CH 严重程度(如血清 TSH 和 FT4 水平)或诊断时骨成熟延迟均无影响。受试者工作特征曲线分析显示,24 个月时左甲状腺素剂量需求的截断值为 2.3μg/kg/day 时,对 TCH 的预测敏感性为 71%,特异性为 70%,低于此阈值时预测 TCH。
TCH 是 CH 患者的重要组成部分。24 个月时的左甲状腺素剂量需求在区分伴正常位置腺体 CH 患者的 TCH 和 PCH 方面具有预测作用。